Safety and Efficacy of T10430 Eye Drops in Controlling Paediatric Myopia Progression
Recruiting now · Phase 2 · Has a placebo group
Conditions studied: Myopia
In brief
Axial myopia is a type of nearsightedness that happens when the eye is too long from front to back. This causes distant vision to be blurry. Axial myopia tends to start during childhood and worsens over time (as the eyes continue to grow longer). This can lead to serious eye-related conditions later in life. The aim of T10430 treatment is to stop or slow this progression during childhood and therefore, prevent more serious complications. Animal studies using drugs with a similar mechanism of action as T10430 have demonstrated positive safety results. This study aims to better understand the safety and potential effectiveness of T10430 in children with axial myopia.
Key facts
- Study ID
- NCT07522242
- Run by
- Laboratoires Thea
- People needed
- 200
- Starts
- 2026-01-21
- Expected to finish
- 2027-11-01
- Last updated by the study team
- 2026-04-13
Who can join
Age: 6 and older, up to 11. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Pretoria Eye Institute Research Foundation — Pretoria, South Africa (enrolling)
- IATROS INTERNATIONAL PTY Ltd — Brandwag, South Africa (enrolling)
- Jordan University Hospital — Amman, Jordan
- Irbid Specialty Hospital — Irbid, Jordan
- Pharmaceutical research center at Jordan University of Science and Technology — Irbid, Jordan
- Hôpital Universitaire Tahar Sfar Mahdia — Mahdia, Tunisia
- Hôpital Farhat-Hached — Sousse, Tunisia
- Abdali Hospital — Amman, Jordan
- Hôpital Charles Nicolle — Tunis, Tunisia
- Istiklal Hospital — Amman, Jordan
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.